These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 9786468)

  • 21. In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae.
    Roblin PM; Hammerschlag MR
    Antimicrob Agents Chemother; 1998 Jun; 42(6):1515-6. PubMed ID: 9624507
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro activity of ketolides HMR 3004 and HMR 3647 and seven other antimicrobial agents against Corynebacterium diphtheriae.
    Engler KH; Warner M; George RC
    J Antimicrob Chemother; 2001 Jan; 47(1):27-31. PubMed ID: 11152428
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The in vitro activity of ABT773, a new ketolide antimicrobial agent.
    Andrews JM; Weller TM; Ashby JP; Walker RM; Wise R
    J Antimicrob Chemother; 2000 Dec; 46(6):1017-22. PubMed ID: 11102425
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Postantibiotic suppression of growth of erythromycin A-susceptible and -resistant gram-positive bacteria by the ketolides telithromycin (HMR 3647) and HMR 3004.
    Munckhof WJ; Borlace G; Turnidge JD
    Antimicrob Agents Chemother; 2000 Jun; 44(6):1749-53. PubMed ID: 10817748
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative in vitro activity of ABT-773 and two macrolides against staphylococci.
    von Eiff C; Peters G
    J Antimicrob Chemother; 2002 Jan; 49(1):189-92. PubMed ID: 11751787
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative in vitro activity of telithromycin (HMR 3647), three macrolides, amoxycillin, cefdinir and levofloxacin against gram-positive clinical isolates in Japan.
    Okamoto H; Miyazaki S; Tateda K; Ishii Y; Yamaguchi K
    J Antimicrob Chemother; 2000 Nov; 46(5):797-802. PubMed ID: 11062201
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The ketolide antibiotic HMR 3647, a candidate substance for the treatment of systemic and intracerebral infections with Listeria monocytogenes.
    Nichterlein T; Kretschmar M; Hof H
    Zentralbl Bakteriol; 1999 Apr; 289(2):155-64. PubMed ID: 10360316
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to two ketolides (HMR 3004 and HMR 3647), four macrolides (azithromycin, clarithromycin, erythromycin A, and roxithromycin), and two ansamycins (rifampin and rifapentine).
    Hoppe JE; Bryskier A
    Antimicrob Agents Chemother; 1998 Apr; 42(4):965-6. PubMed ID: 9559823
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative in vitro activity of ABT-773, a novel antibacterial ketolide.
    Nilius AM; Bui MH; Almer L; Hensey-Rudloff D; Beyer J; Ma Z; Or YS; Flamm RK
    Antimicrob Agents Chemother; 2001 Jul; 45(7):2163-8. PubMed ID: 11408246
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In-vitro activity of RP 59500, a new semisynthetic streptogramin antibiotic, against gram-positive bacteria.
    Brumfitt W; Hamilton-Miller JM; Shah S
    J Antimicrob Chemother; 1992 Jul; 30 Suppl A():29-37. PubMed ID: 1399948
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro activity of ABT773, a new ketolide derivative exhibiting innovative microbiological properties against well-characterised antibiotic resistant pathogens in Italy.
    Bozzolasco M; Debbia EA; Roveta S; Schito AM; Marchese A
    Int J Antimicrob Agents; 2004 Jan; 23(1):11-6. PubMed ID: 14732308
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens.
    Agouridas C; Denis A; Auger JM; Benedetti Y; Bonnefoy A; Bretin F; Chantot JF; Dussarat A; Fromentin C; D'Ambrières SG; Lachaud S; Laurin P; Le Martret O; Loyau V; Tessot N
    J Med Chem; 1998 Oct; 41(21):4080-100. PubMed ID: 9767644
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vivo efficacy of the new ketolide telithromycin (HMR 3647) in murine infection models.
    Bonnefoy A; Guitton M; Delachaume C; Le Priol P; Girard AM
    Antimicrob Agents Chemother; 2001 Jun; 45(6):1688-92. PubMed ID: 11353612
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro and in vivo efficacy of a novel fluoro-ketolide HMR 3562 against enterococci.
    Guitton M; Delachaume C; Le Priol P; Steier V; Bonnefoy A
    J Antimicrob Chemother; 2001 Jul; 48(1):131-5. PubMed ID: 11418524
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ketolides lack inducibility properties of MLS(B) resistance phenotype.
    Bonnefoy A; Girard AM; Agouridas C; Chantot JF
    J Antimicrob Chemother; 1997 Jul; 40(1):85-90. PubMed ID: 9249208
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro activities of ketolides HMR 3647 [correction of HRM 3647] and HMR 3004 [correction of HRM 3004], levofloxacin, and other quinolones and macrolides against Neisseria spp. and Moraxella catarrhalis.
    Sáez-Nieto JA; Vázquez JA
    Antimicrob Agents Chemother; 1999 Apr; 43(4):983-4. PubMed ID: 10103218
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A new ketolide, HMR 3004, active against streptococci inducibly resistant to erythromycin.
    Rosato A; Vicarini H; Bonnefoy A; Chantot JF; Leclercq R
    Antimicrob Agents Chemother; 1998 Jun; 42(6):1392-6. PubMed ID: 9624482
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Susceptibility in vitro of gram-positive aerobe and anaerobe bacteria to ofloxacin.
    Debbia E; Mannelli S; Gianrossi G; Schito GC
    Drugs Exp Clin Res; 1987; 13(4):213-7. PubMed ID: 3304918
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activities of HMR 3004 (RU 64004) and HMR 3647 (RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and eight other antimicrobial agents against unusual aerobic and anaerobic human and animal bite pathogens isolated from skin and soft tissue infections in humans.
    Goldstein EJ; Citron DM; Hunt Gerardo S; Hudspeth M; Merriam CV
    Antimicrob Agents Chemother; 1998 May; 42(5):1127-32. PubMed ID: 9593139
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative in vitro activity of the new erythromycin derivative dirithromycin against gram-positive bacteria isolated from cancer patients.
    Rolston KV; Ho DH; LeBlanc B; Bodey GP
    Eur J Clin Microbiol Infect Dis; 1990 Jan; 9(1):30-3. PubMed ID: 2137413
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.